Endothelial EGLN3-PKM2 signaling induces the formation of acute astrocytic barrier to alleviate immune cell infiltration after subarachnoid hemorrhage

Mingxu Duan,Xufang Ru,Jiru Zhou,Yuanshu Li,Peiwen Guo,Wenbo Kang,Wenyan Li,Zhi Chen,Hua Feng,Yujie Chen

DOI: https://doi.org/10.1186/s12987-024-00550-8

2024-05-19

Fluids and Barriers of the CNS

Abstract:Most subarachnoid hemorrhage (SAH) patients have no obvious hematoma lesions but exhibit blood–brain barrier dysfunction and vasogenic brain edema. However, there is a few days between blood‒brain barrier dysfunction and vasogenic brain edema. The present study sought to investigate whether this phenomenon is caused by endothelial injury induced by the acute astrocytic barrier, also known as the glial limitans.

neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that after subarachnoid hemorrhage (SAH), there is an obvious time - lag phenomenon between blood - brain barrier (BBB) dysfunction and brain edema. Specifically, although obvious BBB injury can be observed on the first day after SAH, brain edema in most neuro - critical patients occurs within 3 to 7 days after SAH. This time difference suggests that there may be some changes in mechanism or structure between BBB injury and brain edema, which can temporarily protect brain tissue from further damage. Therefore, the researchers hypothesized that in the acute phase of SAH, astrocytes may maintain the barrier function by forming a temporary protective barrier - glia limitans, reduce the invasion of immune cells, and thus reduce early brain injury. In addition, the study also explored how the EGLN3 - PKM2 signaling pathway in endothelial cells affects this process and its potential therapeutic significance for improving the prognosis of SAH patients.

Specifically, the main objectives of the paper are:
1. **Explore the reasons for the time - lag phenomenon between BBB dysfunction and brain edema after SAH**: In particular, whether astrocytes temporarily protect brain tissue by forming glia limitans.
2. **Clarify the role of the EGLN3 - PKM2 signaling pathway in endothelial cells in this process**: Including how this signaling pathway promotes the formation of glia limitans and its specific mechanism for reducing brain injury.
3. **Evaluate the potential of the EGLN3 - PKM2 signaling pathway as a new target for SAH treatment**: By regulating this signaling pathway, whether the prognosis of SAH patients can be improved.

The achievement of these objectives will help to deeply understand the mechanism of brain injury after SAH and provide a theoretical basis for the development of new treatment methods.